NEW YORK, July 11, 2018 /PRNewswire/ -- Executives with the innovative late development-stage pharmaceutical startup, Bridge Therapeutics, announced they will be introducing their chronic pain development program at the American Chronic Pain Association (ACPA) Roundtable.
The ACPA offers peer support and education in pain management skills to people with chronic pain, along with their families, friends, and healthcare professionals.
The organization promotes facilitating peer support and education on chronic pain illnesses and treatments so that patients with chronic pain may lead fuller lives.
Alton Kelley, Director of Business Development for Bridge Therapeutics, said this roundtable will give the chronic pain community an opportunity to learn more about Bridge Therapeutics' current developments on pain relievers and promoting the ACPA's efforts in fighting chronic pain.
"The overlap between the ACPA mission and our mission at Bridge Therapeutics made this collaboration inevitable," Kelley said. "Bringing our ideas and solutions to the chronic pain community through the ACPA provides a great service to those in need of pain relief while reducing the impact of the current opioid epidemic."
Colleagues Tim Peara and Morgan Wagner with Bridge Therapeutics will join Kelley at the ACPA Roundtable, which takes place from July 12-13 in New York City at The Muse Hotel.
The Growing Opioid Crisis
Bridge Therapeutics is currently working to bring new chronic pain medications to the market. The pharmaceutical startup aims to reduce the impact of the opioid crisis by seeking alternatives to drugs that lead to opioid addiction.
ACPA and Bridge Therapeutics will collaborate at the roundtable, discussing new alternatives for safely treating chronic pain. Kelley says this collaboration will allow both companies to share their work, development projects and identify alternative treatment programs to help patients suffering from chronic pain.
About Bridge Therapeutics
Bridge Therapeutics is an innovative development-stage specialty pharmaceutical company pursuing U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals of a patented (U.S. Patent #8410092) drug combination, BT-205, for the treatment of chronic pain in opioid-experienced patients. The investigational drug BT-205 is a unique combination of two chronic pain drugs — the partial-agonist opioid buprenorphine and the NSAID meloxicam — delivered in a state-of-the-art sublingual formulation. The dosing and delivery method will be a commercial advantage over current alternatives. Bridge Therapeutics' goal is to make the BT-205 compound and other investigational new drug candidates available to millions of patients experiencing chronic pain.
Press Contact: Mark Macias
SOURCE Bridge Therapeutics